IART icon

Integra LifeSciences

24.10 USD
+0.86
3.70%
At close Jan 17, 4:00 PM EST
After hours
24.10
+0.00
0.00%
1 day
3.70%
5 days
11.37%
1 month
4.65%
3 months
21.96%
6 months
-23.85%
Year to date
4.69%
1 year
-42.47%
5 years
-59.24%
10 years
-14.05%
 

About: Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

Employees: 3,946

0
Funds holding %
of 6,823 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

2,639% more call options, than puts

Call options by funds: $10.6M | Put options by funds: $388K

6% less funds holding

Funds holding: 237 [Q2] → 222 (-15) [Q3]

7.51% less ownership

Funds ownership: 98.26% [Q2] → 90.75% (-7.51%) [Q3]

22% less first-time investments, than exits

New positions opened: 51 | Existing positions closed: 65

24% less repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 82

45% less capital invested

Capital invested by funds: $2.26B [Q2] → $1.24B (-$1.01B) [Q3]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$22
9%
downside
Avg. target
$22
9%
downside
High target
$22
9%
downside

1 analyst rating

positive
0%
neutral
0%
negative
100%
Citigroup
Joanne Wuensch
60% 1-year accuracy
28 / 47 met price target
9%downside
$22
Sell
Maintained
5 Nov 2024

Financial journalist opinion

Based on 6 articles about IART published over the past 30 days

Positive
Zacks Investment Research
5 hours ago
4 Intriguing Value Stocks to Add to Your Portfolio Now
Value investing is essentially about selecting cheap but fundamentally sound stocks. TSN, GM, IART and ENS boast low P/CF ratios.
4 Intriguing Value Stocks to Add to Your Portfolio Now
Neutral
GlobeNewsWire
6 days ago
Integra LifeSciences Launches Integra Institute for Healthcare Professionals (HCPs)
New global medical education platform offers digital tools to keep HCPs at the forefront of medical knowledge New global medical education platform offers digital tools to keep HCPs at the forefront of medical knowledge
Integra LifeSciences Launches Integra Institute for Healthcare Professionals (HCPs)
Neutral
Zacks Investment Research
2 weeks ago
IART or PEN: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Integra LifeSciences (IART) or Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?
IART or PEN: Which Is the Better Value Stock Right Now?
Positive
Zacks Investment Research
2 weeks ago
Invest in These 4 Value Stocks for Promising 2025 Returns
Value investing is essentially about selecting stocks that are cheap but fundamentally sound. TSN, GM, MGNI & IART boast a low P/CF ratio.
Invest in These 4 Value Stocks for Promising 2025 Returns
Positive
Zacks Investment Research
2 weeks ago
Is Integra LifeSciences (IART) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Integra LifeSciences (IART) a Great Value Stock Right Now?
Positive
Zacks Investment Research
2 weeks ago
Here's Why You Should Hold IART Stock in Your Portfolio Now
Integra's growth within its Tissue Technologies business segment bolsters investors' confidence in the stock.
Here's Why You Should Hold IART Stock in Your Portfolio Now
Positive
Zacks Investment Research
1 month ago
Reasons to Retain IART Stock in Your Portfolio for Now
Integra's strong growth in the CSS business segment bolsters investors' confidence in the stock. Meanwhile, the weak liquidity position adds to the worry.
Reasons to Retain IART Stock in Your Portfolio for Now
Positive
Zacks Investment Research
2 months ago
IART Stock to Gain From New Study Findings on DuraSeal Dural Sealant
According to a health economic evaluation, Integra's DuraSeal Dural Sealant is revealed to reduce healthcare costs.
IART Stock to Gain From New Study Findings on DuraSeal Dural Sealant
Neutral
GlobeNewsWire
2 months ago
Integra's DuraSeal® Dural Sealant Saves Healthcare Costs According to an Economic Evaluation Published in the Journal of Comparative Effectiveness Research
The health economic analysis, conducted in five European countries, shows that hospitals can reduce costs of cerebrospinal fluid leaks after posterior cranial fossa surgeries by using DuraSeal dural sealant instead of fibrin glue The health economic analysis, conducted in five European countries, shows that hospitals can reduce costs of cerebrospinal fluid leaks after posterior cranial fossa surgeries by using DuraSeal dural sealant instead of fibrin glue
Integra's DuraSeal® Dural Sealant Saves Healthcare Costs According to an Economic Evaluation Published in the Journal of Comparative Effectiveness Research
Neutral
Zacks Investment Research
2 months ago
Integra Q3 Earnings, Revenues Beat, Stock Up Despite Margin Pressure
IART is optimistic about the fact that the shipping holds have largely been resolved within the third quarter.
Integra Q3 Earnings, Revenues Beat, Stock Up Despite Margin Pressure
Charts implemented using Lightweight Charts™